Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Low-Temperature Fabrication of Thymosin β4-Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22rɑ2

He S., Yuan M., Feng C., Zhang Y., Che J.

Animal Study on Chronic Wound, Immune Modulation, published in Adv Healthc Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Healthc Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41467542
PMCID
PMC13015770
DOI
10.1002/adhm.202504878

Abstract (original English)

Skin wound treatment is hindered by the poor penetration of large therapeutics and a lack of treatments that effectively regulate immune environments. While microneedles (MNs) can bypass the skin, they destabilize sensitive peptides, including thymosin β4 (Tβ4), whose immunomodulatory targets are not well understood, limiting their clinical use. This study introduces a novel fabrication method for Tβ4-loaded soluble MNs at low temperatures using chitosan and sucrose, avoiding the denaturing conditions of traditional MN production. These MNs exhibit a uniform shape, high drug capacity (248.15 ± 1.37 µg/patch), quick dissolution within an hour, excellent biocompatibility, and significantly enhanced wound healing in mice. This study examines the mechanism by which Tβ4 accelerates wound healing, identifying the downregulated immune regulators Spp1, Vsig4, and IL22rɑ2 through RNA-seq and DEG analysis. In vitro qPCR, western blot, and surface plasmon resonance (SPR) experiments demonstrate that Tβ4 specifically binds to the downregulated immune regulators Vsig4 (K D = 3.56 × 10 -6 m) and IL22rɑ2 (K D = 9.69 × 10 -6 m). This article explores how Tβ4 influences the wound immune microenvironment to aid healing, identifies its specific molecular targets, and moves beyond its general roles to offer new opportunities for drug development.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
SkinAnimalsHumansMiceThymosinNeedlesWound HealingDown-RegulationCold Temperature

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research